December 4, 2019
November 22, 2019
October 22, 2019
January 13, 2020
Over the past year, we have had many reasons to be proud of the promising work supported by the ADDF. The following is a summary of what I see as the ADDF’s most important science and research involvements of 2019. As we close out the decade, I am encouraged that we are moving closer to viable therapies and prevention strategies for Alzheimer’s disease.
January 2, 2020
By any definition, Pamela J. Newman, Ph.D. and her late husband Henry (Hank) Kates were a power couple. But when Alzheimer’s struck Hank, suddenly the Newman-Kates family felt powerless. Together, they valiantly fought the disease until Hank’s death in 2016 at age 77. For years, Dr. Newman has been an ardent supporter of Alzheimer’s research and ADDF, serving on the Board of Overseers since 2013. In recognition of her dedication, we recently honored Pamela with the Charles Evans Award at the Tenth Annual “Hope on the Horizon” Fall Symposium & Luncheon in New York City.
December 10, 2019
Chief Medical Officer at Amylyx Pharmaceuticals gives a closer look at how far they have come in their recently expanded phase 2 clinical trial, supported in part by the ADDF, which is studying a combination approach to treating people with Alzheimer’s disease.